NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT07415005 2026-02-17
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT05740943 2026-01-20
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Phase 2 Active not recruiting
NCT05297890 2025-12-23
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
CStone Pharmaceuticals
Phase 2 Active not recruiting
NCT03909971 2025-11-05
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
Pfizer
Phase 2 Completed
NCT04621188 2025-09-24
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT07083687 2025-07-24
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT04111705 2025-04-01
ORAKLE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed